PROpel study backs Lynparza combo in first-line prostate can...

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug's use broadened after a p

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

AstraZeneca and Merck & Co's Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it could extend the time for the cancer to return when

NICE says no to AZ’s Lynparza for prostate cancer

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.

Filing beckons as Lynparza hits the mark in adjuvant breast ...

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial. 

Triple Negative Breast Cancer Drug Development Digital Summi...

Fast-track the Discovery & Development of TNBC

AZ, Merck add pancreatic cancer to Lynparza’s growing use li...